Cynata Therapeutics 대차 대조표 상태

재무 상태 기준 확인 4/6

Cynata Therapeutics 의 총 주주 지분은 A$7.2M 이고 총 부채는 A$0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 A$8.4M 및 A$1.2M 입니다.

주요 정보

부채 비율

AU$0

부채

이자 보상 비율	n/a
현금	AU$6.21m
주식	AU$7.22m
총 부채	AU$1.17m
총 자산	AU$8.39m

최근 재무 상태 업데이트

We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

Feb 02

We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Sep 09

Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

May 26

Recent updates

Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Sep 21

Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?

May 29

We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate

Feb 09

We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

Feb 02

We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Sep 09

Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

May 26

Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Dec 31

We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

Aug 11

재무 상태 분석

단기부채: CYP 의 단기 자산 ( A$6.5M )이 단기 부채( A$1.2M ).

장기 부채: CYP 에는 장기 부채가 없습니다.

부채 대 자본 내역 및 분석

부채 수준: CYP 부채가 없습니다.

부채 감소: CYP 5년 전에 부채가 없었습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: CYP 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 17.9 %의 역사적 비율로 계속 감소할 경우 CYP 의 현금 활주로는 1년 미만입니다.

Cynata Therapeutics 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?

We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate

We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Recent updates

Cynata Therapeutics Limited, Annual General Meeting, Nov 19, 2024

Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

New major risk - Financial position

Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?

Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial

Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001

New minor risk - Financial position

We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate

Cynata Therapeutics Limited Announces Resignation of David Atkins as Director

New major risk - Financial position

Cynata Therapeutics Limited Announces Management Appointments

We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

Cynata Therapeutics Limited Receives IRB Approval for Proposed aGvHD Phase 2 Clinical Trial

Cynata Therapeutics Limited Receives Notice of Acceptance from IP Australia for Novel Application of Cymerus MSCs

LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation

Cynata Therapeutics Limited Receives Notice of Allowance for Australia & Canada Cymerus Patents

Cynata Therapeutics Limited Announces Successful Completion of Planned DSMB Review of DFU Trial

Cynata Therapeutics Limited, Annual General Meeting, Nov 22, 2022

Cynata Therapeutics Limited Receives Grant Award to Fund Study of Cynata Mscs in Heart Disease from Australian Government National Health and Medical Research Council

We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Cynata Therapeutics Limited Appoints Janine Rolfe as Independent Non-Executive Director, Effective 1 September 2022

Cynata Therapeutics Limited Announces Preclinical Study Showing Optimisation of CymerusTM MSCs for Coronary Artery Disease Published in Leading Peer-Reviewed Journal

Cynata Therapeutics Limited Receives Notice of Allowance from US Patent Office for Use of the Cymerus MSCs in Asthma

Cynata Therapeutics Limited Announces the Completion of A Pre-Clinical Study That Has Provided Further Evidence in Support of the Highly Potent Anti-Inflammatory Effects of Cynata's Proprietary Cymerus MSCs

Cynata Therapeutics Limited Adds New Site for MEMD Clinical Trial

United States Food and Drug Administration Clears IND for Cynata Therapeutics Limited's Phase 2 Clinical Trial of CYP-001 in GvHD

Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Price target decreased to AU$2.00

Cynata Therapeutics Limited Advances Clinical Trial in Diabetic Foot Ulcers

Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan

Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan

Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Cynata Therapeutics Limited Commences DFU Clinical Trial

We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

Cynata Therapeutics Limited Receives Approval by the Central Adelaide Local Health Network Human Research Ethics Committee to Commence A Clinical Trial

Cynata Therapeutics Limited Progresses Toward Clinical Trial in Diabetic Foot Ulcers

Cynata Therapeutics Limited Announces First Patient Enrolled in Cynata Mend Clinical Trial

Cynata Therapeutics Limited to Investigate New Study of the High Potency of Cymerus MSCs

New 90-day low: AU$0.64

New 90-day low: AU$0.66

New 90-day low: AU$0.74

Cynata Therapeutics Limited Announces Phase 3 Osteoarthritis Clinical Trial Commences

Cynata Therapeutics Limited Announces Positive Efficacy Data from A Study of Cymerustm Mesenchymal Stem Cells

New 90-day high: AU$1.03

New 90-day high - AU$0.79

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기